Ensysce Biosciences, Inc. — Form 8-K Summary
Reporting date: September 25, 2026. The report was signed September 29, 2026. It covers an amendment to the company’s Series C Non-Voting Convertible Preferred Stock designation; it does not report quarterly or annual financial results.
Material corporate change
Effective upon filing on September 25, the company amended its Series C Certificate of Designation to remove Section 6.5.3 and related references. The deleted provision allowed a Series C holder, after stockholder approval of conversion into common stock, to elect cash redemption if the company failed to deliver common shares as required. The redemption price was to equal the then-current fair value of the Series C Preferred Stock, as described in the designation.
Financial information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics, and no comparative-period results or guidance.
Investor items to verify
- Review the full Certificate of Amendment filed as Exhibit 3 and the amended Series C Certificate of Designation.
- Confirm the applicable stockholder-approval and conversion terms, and assess the effect of removing the cash-redemption remedy if common shares are not delivered.
- Check subsequent filings for updates regarding the Series C Preferred Stock and any related stockholder approval.